Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 44 for “"allo-HSCT"”.
-
Επίπτωση και παράγοντες κινδύνου της αιμορραγικής κυστίτιδας (HC) σε παιδιατρικούς ασθενείς μετά από αλλογενή μεταμόσχευση αιμοποιητικών κυττάρων (allo-HSCT)
Εισαγωγή: Η αιμορραγική κυστίτιδα (ΑΚ) μπορεί να είναι μια σοβαρή επιπλοκή στη μεταμόσχευση αιμοποιητικών κυττάρων (ΜΑΚ). Παρόλαυτα ο λόγος και ο προσδιορισμός των παραγόντων κινδύνου ειδικά όσο αφορά στους παιδιατρικούς ασθενείς δεν είναι ξεκάθαρη και χρήζει επιπλέον διερεύνησης. Υλικό - Μέθοδοι: …
-
The vasculature and immune cell reconstitution of the bone marrow niche after allogeneic hematopoietic stem cell transplantation
… malignant diseases of the hematopoietic system, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option. Unfortunately, more than half of the patients receiving allo-HSCT die within the first two years. A major reason for mortality after allo-HSCT is …
-
Anti-Aspergillus-IgG-Bestimmung zur Vorhersage der pulmonalen invasiven Aspergillose nach allogener Stammzelltransplantation
… schwerwiegende Komplikation bei Patienten nach allogener Stammzelltransplantation (allo-HSCT). Um eine IA durch die Inhalation luftgetragener Sporen zu verhindern, werden in allen Transplantationszentren Luftfiltersysteme eingesetzt. In aktuellen Veröffentlichungen wurde demonstriert, dass die …
-
Treatment Outcomes in Children with Very High Risk Acute Lymphoblastic Leukemia Intended to Treat with Allogeneic Hematopoietic Stem Cell Transplantation
… in spite of intensive chemotherapy. Recently, allogeneic hematopoietic stem cell transplantation (Allo-HSCT) was use to treat the patients with VHR ALL. We studied the clinical course and outcomes of children with VHR ALL intended treat with Allo-HSCT after chemotherapy. 16 children who were …
-
Contribution to the study of the immune response to the BNT162b2 vaccine in allogeneic hematopoietic stem cell transplant
Allogeneic Hematopoietic Stem Cell transplantation (allo-HSCT) is the best treatment option for patients affected by different kinds of blood diseases, especially malignancy. It consists in the graft of new hematopoietic stem cells (HSCs) from a selected donor into a receiver so to create a new …
-
Μελέτη της επίδρασης της μεταμόσχευσης αιμοποιητικών κυττάρων στο αγγειακό ενδοθήλιο
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only treatment option for a variety of malignant and non-malignant hematological diseases. However, during allo-HSCT, the endothelial cells (ECs) of the body's vessels face multiple challenges, resulting in …
-
Einfluss von Anti-Thymozyten-Globulin und Defibrotid auf die Proliferation, Migration und angiogene Aktivität von Endothelzellen
EINLEITUNG: Die allogene hämatopoietische Stammzelltransplantation (hematopoietic stem cell transplantation, allo-HSCT) ist eine Standardtherapie zur Behandlung von akuten Leukämien und anderen hämatologischen Neoplasien. Wesentliche Komplikationen der allo-HSCT sind Graft-versus-Host-Disease …
-
MICRORNA-21 REGULATES CELL-INTRINSIC DONOR T CELL ALLOREACTIVITY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for blood cancers. Its efficacy depends on donor T lymphocytes recognizing and eliminating residual malignant cells through the graft-versus-leukemia (GVL) effect. However, up to 50% of recipients develop …
-
Eine vergleichende Untersuchung unterschiedlicher Strategien der Darmdekontamination bei der allogenen Stammzelltransplantation
… des intestinalen Mikrobioms auf die allo HSCT sind komplex und bis heute noch nicht vollständig verstanden. Es bleibt umstritten, inwieweit eine hohe Diversität des Mikrobioms zu einem verbesserten Outcome, zu geringeren Raten an GvHD sowie an Infektionen führt. Vor diesem Hintergrund …
-
Initiation of Acute Graft-versus-Host Disease by Angiogenesis
… diseases of the hematopoietic system, the allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option. Accordingly, the number of allo-HSCTs performed worldwide has increased greatly in the past decades. However, the mortality after allo-HSCT is …
-
Epstein-Barr virus in the pathogenesis of post-transpant lymphoproliferative disease
… and PTLD amongst patients undergoing allogeneic haematopoietic stem cell transplant (allo-HSCT) revealed greatly reduced risk amongst patients with Non-Hodgkin lymphoma previously treated with Rituximab. Complementary laboratory studies to explore the pathophysiology of EBV …
-
Immune responses to human cytomegalovirus (HCMV) reactivation in allogeneic haematopoietic stem cell transplantation (HSCT)
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is commonly used to treat a range of haematological malignancies with Human cytomegalovirus (HCMV) reactivation as one of the major risk factors. HCMV reactivation is crucial as it can lead to HCMV disease and increase mortality. The …
-
Leucine rich alpha-2-glycoprotein 1 bei akuter Graft-versus-Host Erkrankung: Messung von Serumkonzentrationen und funktionelle Analysen
Allogenic hematopoetic stem cell transplantation (allo-HSCT) is the only curative therapy for various hematological diseases. Despite improved conditioning regimes and aGvHD prophylaxis acute Graft-versus-Host Disease remains one of the most frequently observed complications after allo-HSCT. …
-
Angiogenesis in Graft-versus-Host Disease
For a variety of hematopoietic diseases, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option. Due to numerous improvements in the treatment procedure and the constant expansion of indications, the number of transplanted patients has increased rapidly …
-
IDENTIFICAZIONE DI NUOVE VIE DI SEGNALE E MARCATORI PREDITTIVI DELLA MALATTIA DEL TRAPIANTO CONTRO L'OSPITE DOPO TRAPIANTO ALLOGENICO DI CELLULE STAMINALI EMATOPOIETICHE
… PATHWAYS AND PREDICTOR BIOMARKERS OF GVHD AFTER ALLOGENEIC HSCT Background and rationale Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative option for patients with hematological malignancies. However, its success is limited by life-threatening …
-
Enhancing regulatory T cell therapy efficacy for acute GVHD prevention
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a curative option for many hematological disorders. Unfortunately, allo-HSCT efficacy is complicated by graft-versus-host disease (GVHD), a leading cause of morbidity and mortality after transplant. Current GVHD prophylaxis …
-
Applications of data science to investigate risk factors in allogeneic stem cell transplantation
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) from healthy donors can provide curative therapy for a variety of life-threatening haematological malignancies. However, the risk of relapse, graft-vs-host disease (GvHD), infection, and toxicity remain major causes of mortality. …
-
Investigation of the effects of LSD1 inhibition on AML immunogenicity and T cell-mediated immune responses
… (AML) is an aggressive hematological malignancy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a curative treatment option for AML. Alloreactive donor T cells can produce the graft-versus-leukemia (GVL) effect which represents a major therapeutic benefit of allo-HSCT. …
-
Contribution à l’étude de la maladie du greffon contre l’hôte dans des modèles de souris humanisées
… des réponses du système immunitaire après une allogreffe de cellules souches hématopoïétiques (allo-HSCT), mettant l'accent sur la prévention de la GVHD et l'amélioration de l'effet GvT. Mes projets englobent une variété d'approches novatrices. Dans une démarche translationnelle, mes …
-
Methods to enhance the efficacy of Regulatory T-cell therapies for acute and chronic Graft-versus-Host Disease
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving, curative treatment for a range of malignant and non-malignant diseases. However, the efficacy of allo-HSCT is significantly reduced by the development of acute and chronic graft-versus-host disease (GVHD). Current GVHD …
Page 1 of 3